Synergistic Approach of Antibody-Photosensitizer Conjugate Independent of KRAS-Mutation and Its Downstream Blockade Pathway in Colorectal Cancer

被引:6
作者
Ahn, Minji [1 ,2 ]
Lee, Taebum [1 ,2 ]
Kim, Kyoung Sub [2 ]
Lee, Sanghee [3 ]
Na, Kun [1 ,2 ]
机构
[1] Catholic Univ Korea, Dept Biomed Chem Engn, 43 Jibong Ro, Bucheon Si 14662, Gyeonggi Do, South Korea
[2] Catholic Univ Korea, Dept Biotechnol, 43 Jibong Ro, Bucheon Si 14662, Gyeonggi Do, South Korea
[3] Northwestern Univ, Feinberg Sch Med, Dept Radiol, Chicago, IL 60611 USA
基金
新加坡国家研究基金会;
关键词
antibody drug conjugates; cetuximab conjugates; KRAS mutation; linker chemistry; photoimmunotherapy; EGFR-TARGETED THERAPIES; DRUG; RESISTANCE; CETUXIMAB; LINKERS;
D O I
10.1002/adhm.202302374
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Here, a novel approach is presented to improve the efficacy of antibody-drug conjugates (ADC) by integrating antibody-mediated immunotherapy and photodynamic therapy (PDT) in a combination therapy system utilizing an antibody-photosensitizer conjugate (APC) platform based on a poloxamer polymer linker. To specifically target Kirsten rat sarcoma 2 viral oncogene homolog (KRAS)-mutated cancer cells, an antibody antiepidermal growth factor receptor (EGFR), cetuximab, with a poloxamer linker coupled with the photosensitizer chlorin e6 through click chemistry (cetuximab-maleimide-poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide)-chlorine e6 conjugate, CMPXC) is synthesized. CMPXC is cytotoxic upon laser treatment, achieving a 90% cell death by suppressing KRAS downstream signaling pathways associated with ERK and AKT proteins, confirmed using RNA sequencing analysis. In KRAS-mutated colorectal cancer mouse models, CMPXC significantly enhances antitumor efficacy compared with cetuximab treatment alone, resulting in an 86% reduction in tumor growth. Furthermore, CMPXC treatment leads to a 2.24- and 1.75-fold increase in dendritic and priming cytotoxic T cells, respectively, highlighting the immune-activating potential of this approach. The findings suggest that the APC platform addresses the challenges associated with ADC development and EGFR-targeted therapy, including the synergistic advantages of antibody-mediated immunotherapy and PDT. To improve the efficacy of antibody-drug conjugates, a novel platform by combining antibody-mediated immunotherpay and photodynamic therapy is constructed. Upon spatiotemporal light exposure, the antibody-photosensitizer conjugate exhibits a remarkable anticancer effect, independent Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutation, by suppressing KRAS downstream signaling pathways and providing innate and adaptive immune system induction through a synergistic approach.image
引用
收藏
页数:12
相关论文
共 49 条
  • [1] Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future
    Alzeibak, Razan
    Mishchenko, Tatiana A.
    Shilyagina, Natalia Y.
    Balalaeva, Irina V.
    Vedunova, Maria V.
    Krysko, Dmitri V.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (01)
  • [2] Strategies and challenges for the next generation of antibody drug conjugates
    Beck, Alain
    Goetsch, Liliane
    Dumontet, Charles
    Corvaia, Nathalie
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2017, 16 (05) : 315 - 337
  • [3] Antibody-drug conjugates Present and future
    Beck, Alain
    Reichert, Janice M.
    [J]. MABS, 2014, 6 (01) : 15 - 17
  • [4] Impact of Payload Hydrophobicity on the Stability of Antibody-Drug Conjugates
    Buecheler, Jakob W.
    Winzer, Matthias
    Tonillo, Jason
    Weber, Christian
    Gieseler, Henning
    [J]. MOLECULAR PHARMACEUTICS, 2018, 15 (07) : 2656 - 2664
  • [5] Photodynamic therapy and anti-tumour immunity
    Castano, Ana P.
    Mroz, Pawel
    Hamblin, Michael R.
    [J]. NATURE REVIEWS CANCER, 2006, 6 (07) : 535 - 545
  • [6] The quest to overcome resistance to EGFR-targeted therapies in cancer
    Chong, Curtis R.
    Jaenne, Pasi A.
    [J]. NATURE MEDICINE, 2013, 19 (11) : 1389 - 1400
  • [7] Drug therapy: EGFR antagonists in cancer treatment
    Ciardiello, Fortunato
    Tortora, Giampaolo
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (11) : 1160 - 1174
  • [8] Antibody-drug conjugates in solid tumors: a look into novel targets
    Criscitiello, Carmen
    Morganti, Stefania
    Curigliano, Giuseppe
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
  • [9] Dinu D, 2014, J Med Life, V7, P581
  • [10] Extracellular region of epidermal growth factor receptor: a potential target for anti-EGFR drug discovery
    Dokala, A.
    Thakur, S. S.
    [J]. ONCOGENE, 2017, 36 (17) : 2337 - 2344